Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.
The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. Imlifidase is currently under review for a potential marketing authorization by European Medicines Agency (EMA).
Astellas Pharma Limited
On the forefront of healthcare change, Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients worldwide.
Astellas Pharma is a global pharmaceutical company with a simple vision – to produce exceptional medicines that change tomorrow for patients in need. We strive to develop therapies that are first-in-class and best-in-class. Treatments that offer patients and their doctors genuinely new options for improving care.
Novartis develops, manufactures and markets innovative medicines, devices and diagnostic tests which help improve patient outcomes.
Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products. From beginnings in the production of synthetic fabric dyes, the companies that eventually became Novartis branched out into producing chemicals and ultimately pharmaceuticals.
Sandoz, a division of the Novartis Group, is a global leader in generic medicines, and is committed to playing a leading role in driving access to medicines worldwide.
Sandoz contributes to society’s ability to support growing healthcare needs by pioneering a variety of approaches to help people around the world access high-quality medicine.
Chiesi Limited are an international company with a strong focus on innovative medicines in Respiratory, Neonatology, Special Care and Rare Diseases.
Transplantation is the latest therapy area for Chiesi and an area to which they are committed to developing further as part of a growing Special Care portfolio.
Chiesi Limited are proud to be a Gold Partner to The British Transplantation Society and to provide education and support to transplant specialists and patients in the UK.